• Something wrong with this record ?

Na(+)/K(+)-ATPase inhibition by cisplatin and consequences for cisplatin nephrotoxicity

M. Kubala, J. Geleticova, M. Huliciak, M. Zatloukalova, J. Vacek, M. Sebela

. 2014 ; 158 (2) : 194-200. [pub] 20140429

Language English Country Czech Republic

Document type Journal Article, Research Support, Non-U.S. Gov't

AIMS: Cisplatin is a widely used chemotherapeutic. However, it is associated with numerous adverse effects. The aim of our study was examination of cisplatin interaction with Na(+)/K(+)-ATPase (NKA, the sodium pump). This enzyme is of crucial importance for all animal cells and particularly for the kidney, which is frequently damaged during chemotherapy. METHODS: The entire NKA was isolated from porcine kidney. Its large cytoplasmic segment connecting transmembrane helices 4 and 5 (C45), was heterologously expressed in E.coli (wild-type or C367S mutant). The ATPase activity was evaluated according to the inorganic phosphate production and the interaction of isolated C45 with cisplatin was studied using chronopotentiometry and mass spectrometry. RESULTS: Our experiments revealed that cisplatin can inhibit NKA. The finding that other platinum-based drugs with a low nephrotoxicity, carboplatin and oxaliplatin, did not inhibit NKA, suggested that NKA/cisplatin interaction is an important factor in cisplatin adverse effects. The inhibitory effect of cisplatin could be prevented by preincubation of the enzyme with reduced glutathione or DTT. Using chronopotentiometry and mass spectrometry, we found that cisplatin is bound to C45. However, our mutagenesis experiment did not confirm that the suggested Cys367 could be the binding site for cisplatin. CONCLUSION: Unintended interactions of drugs present serious limitations to treatment success. Although a large number of membrane pumps have been identified as potential targets of cisplatin, vis-a-vis nephrotoxicity, NKA inhibition seems to be of crucial importance. Experiments with isolated large cytoplasmic segment C45 revealed that it is the main target of cisplatin on NKA and that the reaction with cysteine residues plays an important role in cisplatin/NKA interactions. However, further experiments must be performed to identify the interacting amino acid residues more precisely.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15033220
003      
CZ-PrNML
005      
20151030145020.0
007      
ta
008      
151016s2014 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2014.018 $2 doi
035    __
$a (PubMed)24781046
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Kubala, Martin, $u Department of Biophysics, Centre of the Region Hana for Biotechnological and Agricultural Research, Palacky University Olomouc, Czech Republic $d 1977- $7 xx0074179
245    10
$a Na(+)/K(+)-ATPase inhibition by cisplatin and consequences for cisplatin nephrotoxicity / $c M. Kubala, J. Geleticova, M. Huliciak, M. Zatloukalova, J. Vacek, M. Sebela
520    9_
$a AIMS: Cisplatin is a widely used chemotherapeutic. However, it is associated with numerous adverse effects. The aim of our study was examination of cisplatin interaction with Na(+)/K(+)-ATPase (NKA, the sodium pump). This enzyme is of crucial importance for all animal cells and particularly for the kidney, which is frequently damaged during chemotherapy. METHODS: The entire NKA was isolated from porcine kidney. Its large cytoplasmic segment connecting transmembrane helices 4 and 5 (C45), was heterologously expressed in E.coli (wild-type or C367S mutant). The ATPase activity was evaluated according to the inorganic phosphate production and the interaction of isolated C45 with cisplatin was studied using chronopotentiometry and mass spectrometry. RESULTS: Our experiments revealed that cisplatin can inhibit NKA. The finding that other platinum-based drugs with a low nephrotoxicity, carboplatin and oxaliplatin, did not inhibit NKA, suggested that NKA/cisplatin interaction is an important factor in cisplatin adverse effects. The inhibitory effect of cisplatin could be prevented by preincubation of the enzyme with reduced glutathione or DTT. Using chronopotentiometry and mass spectrometry, we found that cisplatin is bound to C45. However, our mutagenesis experiment did not confirm that the suggested Cys367 could be the binding site for cisplatin. CONCLUSION: Unintended interactions of drugs present serious limitations to treatment success. Although a large number of membrane pumps have been identified as potential targets of cisplatin, vis-a-vis nephrotoxicity, NKA inhibition seems to be of crucial importance. Experiments with isolated large cytoplasmic segment C45 revealed that it is the main target of cisplatin on NKA and that the reaction with cysteine residues plays an important role in cisplatin/NKA interactions. However, further experiments must be performed to identify the interacting amino acid residues more precisely.
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorové látky $x škodlivé účinky $x chemie $x farmakologie $7 D000970
650    _2
$a cisplatina $x škodlivé účinky $x chemie $x farmakologie $7 D002945
650    _2
$a ledviny $x enzymologie $7 D007668
650    _2
$a sodíko-draslíková ATPasa $x antagonisté a inhibitory $x chemie $7 D000254
650    _2
$a spektrometrie hmotnostní - ionizace laserem za účasti matrice $7 D019032
650    _2
$a prasata $7 D013552
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Geletičová, Jaroslava $7 _AN084818 $u Department of Biophysics, Centre of the Region Hana for Biotechnological and Agricultural Research, Palacky University Olomouc, Czech Republic
700    1_
$a Huličiak, Miroslav $7 _AN084819 $u Department of Biophysics, Centre of the Region Hana for Biotechnological and Agricultural Research, Palacky University Olomouc, Czech Republic
700    1_
$a Zatloukalová, Martina, $d 1986- $7 xx0170505 $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University Olomouc
700    1_
$a Vacek, Jaroslav $7 xx0125768 $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University Olomouc
700    1_
$a Šebela, Marek, $d 1971- $7 jo20000082920 $u Department of Protein Biochemistry and Proteomics, Centre of the Region Hana for Biotechnological and Agricultural Research, Palacky University Olomouc
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czech Republic $x 1213-8118 $g Roč. 158, č. 2 (2014), s. 194-200
856    41
$u http://biomed.papers.upol.cz/ $y domovská stránka časopisu
910    __
$a ABA008 $b A 1502 $c 958 $y 4 $z 0
990    __
$a 20151016 $b ABA008
991    __
$a 20151029083147 $b ABA008
999    __
$a ok $b bmc $g 1095622 $s 916351
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 158 $c 2 $d 194-200 $e 20140429 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
LZP    __
$b NLK118 $a Pubmed-20151016

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...